STOCKHOLM, Sweden, 2 February 2024 – Avia Pharma Holding AB (“Avia” or the “Company”) has completed the acquisition of Neubourg Skin Care GmbH (“Neubourg”), a leading German dermatology company, specialized in skin, foot and nail care. Through the acquisition, Avia adds a strong dermatology brand portfolio in Germany to its platform,
STOCKHOLM, Sweden, 2 February 2024 – During January, Avia Pharma Holding AB (“Avia” or the “Company”), welcomed Impilo AB as a new owner and partner to the co-founders. Impilo is a Nordic investment company focused on long-term investments in sustainable healthcare companies. The partnership with Impilo will allow Avia to execute
Avia Pharma has today completed the acquisition of ACO Vitamin D water and will as the new marketing authorisation holder re-launch the pharmaceutical in the Swedish market in Q4 this year. “The acquisition allows us to continue offering this complement to D-vitamin oil”, says Marie Wikman, Business Unit Director Avia
Avia Pharma is launching Nyvigan in Swedish pharmacies. Nyvigan (nystatin) is a combination treatment (pessaries + cream) for the treatment of vulvovaginal Candida. Vulvovaginal candidiasis is an infection of the estrogenised vagina and vestibulum which can also extend to the outer sides of the labia minora, the labia majora, the
Avia Pharma has today completed the acquisition of Unimedic’s Vitamin D oil. “The acquisition is in line with Avia Pharma’s strategy to own more products and will complement our existing portfolio”, says Jacob Calmvik, CEO of Avia Pharma. For further information, please contact Jacob Calmvik, CEO Avia Pharma, jacob.calmvik@aviapharma.se, +46 703
Avia Pharma has today completed the acquisition of Allergika Pharma GmbH. The company has a turnover of close to 15 million EUR and is placed in Wolfratshausen, near Munich. Allergika is a German pharmaceutical company focused on the allergy market. It sells both dermatology products and encasing under its own
Avia Pharma has today completed the acquisition of Decem Pharma. Decem Pharma is a Finish pharmaceutical company with its own brands with strong market positions, such as Magnecit and Otocur. The acquisition of Decem Pharma is Avia Pharma’s first acquisition outside of Sweden and part of its strategy to build
Avia Pharma are happy to announce that we have further deepen our relationship with Perrigo to include Dentosal, a much appreciated tooth paste, on the Nordic market.
The pharmaceutical company Avia Pharma has acquired the Swedish pharmaceutical company Pharmaprim, with a product portfolio consisting of drugs in urology, rheumatology and endocrinology.
On December 31, 2019, Avia Pharma acquired the rights to ACO Karbamid and ACO Glycerol from Perrigo.
Following a strong sales increase in the current portfolio, Viiral AS have trusted Avia Pharma to launch Viiral on the Nordic market.
With a strong foot print in women’s health Avia Pharma are trusted to launch Femarelle in Finland.
Following a strong sales increase in the current portfolio, Avia Pharma and Perrigo have deepened the relationship to also include Vectavir®, Vectatone®, Oralmedic® and Predictor®.
Avia Pharma has signed a long-term license agreement with Endoceutics for the Nordic commercial rights to Intrarosa®.
Avia Pharma appoints Mattias Wik as Business Unit Director Oncology/Urology.
Currently there are two Vitamin D drops being sold on the Swedish market. ACO Vitamin D drops does not contain palm oil but the competing product does.
Following a very strong sales increase for all products, Omega Pharma and Avia Pharma has decided to expand their co-operation.
Avia Pharma appoints Marie Wikman as Business Unit Director OTC.
Avia Pharma and Dr Pfleger have entered into a long-term license agreement for Spasmex (Trospium) and Vagitin (Nystatin). The license for Spasmex covers Sweden and Norway and the license for Vagitin covers all Nordic countries.
The Swedish MPA has approved a new formulation of ACO Vitamin D without palm oil.
Avia Pharma AB
Birger Jarlsgatan 27
111 45 Stockholm
Sweden